Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
Recent analysis of case-control studies indicates that NSAIDs are
associated with higher rates of complications following respiratory
tract infections, including complicated pneumonia, pleural effusions,
chronic disease, peritonsillary abscess, spread or suppuration of
infection to more than one site [34]. NSAIDs have also been
associated with delays in prescribing effective antibiotic treatment to
patients requiring admission to hospital. The Food and Drug
Administration (FDA) has released a statement on the use of non- anti-
drugs (NSAIDS) in patients with 2019-nCoV. There are insufficient
clinical evidences to link the use of NSAIDs in worsening COVID-19
symptoms, according to the agency [35].